| 000 | 01854 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518045528.0 | ||
| 264 | 0 | _c20210111 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a1699-3055 | ||
| 024 | 7 |
_a10.1007/s12094-019-02166-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPassaro, A | |
| 245 | 0 | 0 |
_aGr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy. _h[electronic resource] |
| 260 |
_bClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico _cApr 2020 |
||
| 300 |
_a603-611 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBiomarkers |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGranulocytes _xphysiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmune Checkpoint Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aImmunophenotyping |
| 650 | 0 | 4 | _aImmunotherapy |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyeloid-Derived Suppressor Cells _xphysiology |
| 650 | 0 | 4 |
_aNivolumab _xtherapeutic use |
| 650 | 0 | 4 | _aProspective Studies |
| 700 | 1 | _aMancuso, P | |
| 700 | 1 | _aGandini, S | |
| 700 | 1 | _aSpitaleri, G | |
| 700 | 1 | _aLabanca, V | |
| 700 | 1 | _aGuerini-Rocco, E | |
| 700 | 1 | _aBarberis, M | |
| 700 | 1 | _aCatania, C | |
| 700 | 1 | _aDel Signore, E | |
| 700 | 1 | _ade Marinis, F | |
| 700 | 1 | _aBertolini, F | |
| 773 | 0 |
_tClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico _gvol. 22 _gno. 4 _gp. 603-611 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s12094-019-02166-z _zAvailable from publisher's website |
| 999 |
_c29850734 _d29850734 |
||